Predictive value of serum YKL-40 for major adverse cardiovascular events within 30 days after PCI for acute ST-segment elevation myocardial infarction

作者：Caoyang Fang, Zhenfei Chen, Jing Zhang, Jianyuan Pan, Xiaoqin Jin, Mengsi Yang · 发表于：Research Square · 年份：2022 · DOI：10.21203/rs.3.rs-1677248/v1 · 被引用次数：1 · 研究领域：Studies on Chitinases and Chitosanases、Public Health and Nutrition

Abstract Background This study aimed to investigate the predictive value of serum YKL-40 for major adverse cardiovascular events within 30 days after PCI for acute ST-segment elevation myocardial infarction (STEMI). Methods In this study, 120 patients with STEMI admitted to the Second People's Hospital of Hefei from October 2020 to February 2022 were included. All patients received cubital venous blood sampling before PCI to detect serum YKL-40 concentration. Patients were followed up for 30 days after PCI and divided into the MACE group (n = 27) and Non-MACE group (n = 93) according to whether MACE occurred. Univariate and multivariate Cox regression analysis was used to analyze the effect of serum YKL-40 on MACE within 30 days after PCI in STEMI patients. The predictive value of serum YKL-40 for the occurrence of MACE within 30 days after PCI in patients with STEMI was assessed by plotting receiver operating characteristic (ROC) curves. Kaplan-Meier method was used to plot the survival curve of MACE occurring 30 days after PCI in STEMI patients. Results Serum YKL-40 levels were higher in patients in the MACE group than in patients in the Non-MACE group (1431.08±445.31 vs 1028.28±558.47 ng/dL, P < 0.05); Multivariate Cox regression analysis showed that serum YKL-40 was an independent risk factor for MACE events within 30 days after PCI in STEMI patients (OR = 1.002, 95% CI 1.001 – 1.002, P = 0.003); ROC curve analysis showed that the area under the curve (AUC) of serum YK...